Pegvisomant: A growth hormone receptor antagonist for the treatment of acromegaly

Growth Hormone and IGF Research

Volumn 10, Issue SUPPL. B, 2000, Pages

  Parkinson, C ^a   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Growth hormone; Growth hormone receptor antagonist; Pegvisomant treatment

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE ANTAGONIST; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; DIMERIZATION; DRUG EFFICACY; DRUG POTENTIATION; HORMONE ACTION; HORMONE BINDING; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033889361     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(00)80023-4     Document Type: Review

References (34)

1. An audit of outcome of treatment in acromegaly
2. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
3. Tight control of growth hormone: An attainable outcome for acromegaly treatment
4. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
5. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly
6. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience
7. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
8. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients-a clinical research center study
9. Octreotide
10. A prospective multicenter octreotide dose response study in the treatment of acromegaly
11. Long-term treatment of 189 acromegalic patients with the somatostatin analogue octreotide. Results of the International Multicenter Acromegaly Study Group
12. Sandostatin LAR in acromegalic patients: Long-term treatment
13. Results of a European multicentre study with Sandostatin LAR in acromegalic patients
14. Cabergoline in the treatment of acromegaly: A study in 64 patients
15. Signal transduction by receptors with tyrosine kinase activity
16. Crystals of the complex between human growth hormone and the extracellular domain of its receptor
17. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis
18. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis
19. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule
20. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex
21. Amino acid residues in the third alpha-helix of growth hormone involved in growth promoting activity
22. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice
23. Rational design of potent antagonists to the human growth hormone receptor
24. Long-acting growth hormones produced by conjugation with polyethylene glycol
25. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-but does not acutely stimulate serum GH
26. Mortality and cancer incidence in acromegaly: A retrospective cohort study
27. Confusion in clinical and laboratory GH and IGF-I reports
28. Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism
29. Immunogenicity of a mammalian cell-derived recombinant human growth hormone preparation during long-term treatment
30. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone
31. Octreotide as primary therapy for acromegaly